Mezigdomide
Phase 3Small molecule
Bristol-Myers SquibbMezigdomide is one of 78 small molecule programs targeting Leukemia. It is currently in Phase 3.
3
Indications
18
Total Trials
14
Active Trials
77
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Mezigdomide
Bristol-Myers SquibbPhase 3
Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Intron a
Merck & Co.Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma11 trials
Show 8 more trials
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
Recruiting·—·Phase 1·NCT06048250·15 enrolled
Hepatic Impairment1 trial
Relapsed or Refractory1 trial
Renal Impairment1 trial
3 more indications
Relapsed or Refractory Multiple Myeloma1 trial
Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mezigdomide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company